SCHEMBL409917

SCHEMBL409917

COc1ccc(CN(Cc2ccc(OC)cc2)c2nc(CCC(C)=O)nc3c2nc(-n2nccn2)n3C)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 14/20 0.57
ADORA1 P30542 10/20 0.57
ADORA2B P29275 4/20 0.41
ADORA3 P0DMS8 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
KDM4E B2RXH2 1/20 0.37
NPC1 O15118 1/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
MAPT P10636 1/20 0.37
MAOA P21397 1/20 0.37
SLC6A2 P23975 1/20 0.37
RAB9A P51151 1/20 0.37
SLC6A3 Q01959 1/20 0.37
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
USP2 O75604 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL407814 0.81 CCNE2 (0.43) ADORA2AADORA1ADORA2BADORA3LMNA
SCHEMBL13866479 0.76 ADORA2A (0.69) ADORA2AADORA1ADORA2BADORA3SMN1; SMN2
SCHEMBL29421147 0.74 ADORA2A (1.00) ADORA2AADORA1ADORA2BADORA3
SCHEMBL4564669 0.72 ADORA2A (0.51) ADORA2AADORA1ADORA2BADORA3KDM4E
SCHEMBL13866481 0.66 ADORA2A (0.55) ADORA2AADORA1ADORA2BADORA3KDM4E
SCHEMBL2468017 0.62 SMN1; SMN2 (0.72) SMN1; SMN2KDM4ENPC1LMNATP53
SCHEMBL1334 0.62 SMN1; SMN2 (0.72) SMN1; SMN2KDM4ENPC1LMNATP53
SCHEMBL32669303 0.61 LMNA (0.47) SMN1; SMN2KDM4ELMNACYP1A2CYP3A4
Imidazole SCHEMBL9736916 0.60 SMN1; SMN2 (0.52) SMN1; SMN2KDM4ENPC1LMNATP53
SCHEMBL30873421 0.59 LMNA (0.51) SMN1; SMN2NPC1LMNACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160002244-A1 OXIDATED DERIVATIVES OF TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2016-01-07 US disclosed
US-9133197-B2 Oxidated derivatives of triazolylpurines useful as ligands of the adenosine A2A receptor and their use as medicaments SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2015-09-15 US disclosed
EP-2408775-B1 OXIDATED DERIVATIVES OF TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS SIGMA TAU IND FARMACEUTI (IT) 2015-06-17 EP disclosed
US-20120053191-A1 OXIDATED DERIVATIVES OF TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS ALFASIGMA S.P.A. (IT) 2012-03-01 US disclosed
EP-2408775-A1 OXIDATED DERIVATIVES OF TRIAZOLYPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) 2012-01-25 EP disclosed
WO-2010106145-A1 OXIDATED DERIVATIVES OF TRIAZOLYPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053191-A1 OXIDATED DERIVATIVES OF TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS ADORA2A, ADORA3, ADORA1 ADORA2A 1/4885ADORA1 3/4885ADORA2B 4/4885
US-20160002244-A1 OXIDATED DERIVATIVES OF TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS ADORA2A, ADORA3, ADORA1 ADORA2A 1/4885ADORA1 3/4885ADORA2B 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.